GLP-1 and Intestinal Diseases

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

GLP-1 and Intestinal Diseases. / Hunt, Jenna Elizabeth; Holst, Jens Juul; Jeppesen, Palle Bekker; Kissow, Hannelouise.

I: Biomedicines, Bind 9, Nr. 4, 383, 2021.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Hunt, JE, Holst, JJ, Jeppesen, PB & Kissow, H 2021, 'GLP-1 and Intestinal Diseases', Biomedicines, bind 9, nr. 4, 383. https://doi.org/10.3390/biomedicines9040383

APA

Hunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021). GLP-1 and Intestinal Diseases. Biomedicines, 9(4), [383]. https://doi.org/10.3390/biomedicines9040383

Vancouver

Hunt JE, Holst JJ, Jeppesen PB, Kissow H. GLP-1 and Intestinal Diseases. Biomedicines. 2021;9(4). 383. https://doi.org/10.3390/biomedicines9040383

Author

Hunt, Jenna Elizabeth ; Holst, Jens Juul ; Jeppesen, Palle Bekker ; Kissow, Hannelouise. / GLP-1 and Intestinal Diseases. I: Biomedicines. 2021 ; Bind 9, Nr. 4.

Bibtex

@article{baa8b4c79a3042b4aecd8b5a616a4903,
title = "GLP-1 and Intestinal Diseases",
abstract = "Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.",
author = "Hunt, {Jenna Elizabeth} and Holst, {Jens Juul} and Jeppesen, {Palle Bekker} and Hannelouise Kissow",
year = "2021",
doi = "10.3390/biomedicines9040383",
language = "English",
volume = "9",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "4",

}

RIS

TY - JOUR

T1 - GLP-1 and Intestinal Diseases

AU - Hunt, Jenna Elizabeth

AU - Holst, Jens Juul

AU - Jeppesen, Palle Bekker

AU - Kissow, Hannelouise

PY - 2021

Y1 - 2021

N2 - Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.

AB - Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.

U2 - 10.3390/biomedicines9040383

DO - 10.3390/biomedicines9040383

M3 - Review

VL - 9

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 4

M1 - 383

ER -

ID: 259509842